Ensysce Biosciences Inc expected to post a loss of 50 cents a share - Earnings Preview
Ensysce Biosciences Inc <ENSC.OQ> expected to post a loss of 50 cents a share - Earnings Preview
Ensysce Biosciences Inc ENSC.OQ ENSC.O is expected to show a rise in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2026
The La Jolla California-based company is expected to report a 38.6% increase in revenue to $1.9 million from $1.37 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Ensysce Biosciences Inc is for a loss of 50 cents per share.
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ensysce Biosciences Inc is $16.45, about 3,037.5% above its last closing price of $0.52
This summary was machine generated August 7 at 11:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Ensysce Biosciences
See all newsEnsysce Biosciences Q2 net loss widens on higher R&D costs
Ensysce Biosciences Inc expected to post a loss of 50 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Ensysce Biosciences Launches Formal Review Of Strategic Alternatives - SEC Filing